Preoperative Monitoring and Surgical Options for HER2+ Patients
Kandace P. McGuire, MD, provides clinical insights on how patient monitoring practices inform discussions around surgical options, providing the potential for deescalating surgical management.
Read More
Dr. O’Shaughnessy on Adjuvant Abemaciclib in High-Risk Early Breast Cancer
March 1st 2023Joyce O’Shaughnessy, MD, discusses the findings from the phase 3 monarchE trial of adjuvant endocrine therapy with or without abemaciclib in patients with hormone receptor–positive, HER2-negative, node-positive, high-risk early breast cancer.
Read More
Treatment Advances in HR+/HER2- MBC
Final takeaways from a discussion on best practices treating HR+/HER2- metastatic breast cancer with CDK4/6 inhibitors and PI3K therapies based on data presented at ESMO 2021.
Read More
Managing Patients With HR+ MBC on PI3K Therapy
Breast oncologists share pearls regarding best practices treating patients with HR+/HER2- metastatic breast cancer with PI3K inhibitor therapy and mitigating treatment-related adverse events.
Read More
Dr. Joyce O'Shaughnessy on Promising Agents in Triple-Negative Breast Cancer
August 17th 2016Joyce O'Shaughnessy, MD, co-chair, breast cancer research, chair breast cancer at Baylor-Sammons Cancer Center, discusses what’s on the horizon in triple-negative breast cancer (TNBC). Checkpoint inhibitors, such as an anti-PD-1 agents, show a lot of promise in TNBC, said O’Shaughnessy. There are several studies investigating the use of checkpoint inhibitors with platinum agents and the preliminary data looks very good, she said.
Read More